PI3K/AKT Signaling Pathway Mediated Autophagy in Oral Carcinoma - A Comprehensive Review

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2024 May 22

PMID 38774756

Authors

Peramaiyan Rajendran

Ramya Sekar

Prabhu Shankar Dhayasankar

Enas M Ali

Salaheldin Abdelraouf Abdelsalam

Sabarinath Balaraman

Biju Vadakkemukadiyil Chellappan

Ashraf M Metwally

Basem M Abdallah

Affiliations

Soon will be listed here.

Abstract

Oral cancer is the most heterogeneous cancer at clinical and histological levels. PI3K/AKT/mTOR pathway was identified as one of the most commonly modulated signals in oral cancer, which regulates major cellular and metabolic activity of the cell. Thus, various proteins of PI3K/AKT/mTOR pathway were used as therapeutic targets for oral cancer, to design more specific drugs with less off-target toxicity. This review sheds light on the regulation of PI3K/AKT/mTOR, and its role in controlling autophagy and associated apoptosis during the progression and metastasis of oral squamous type of malignancy (OSCC). In addition, we reviewed in detail the upstream activators and the downstream effectors of PI3K/AKT/mTOR signaling as potential therapeutic targets for oral cancer treatment.

Citing Articles

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice.

Zhang X, Lu Q, Li Y, Shi S, Ma C, Miao M Front Pharmacol. 2025; 16:1528250.

PMID: 39963241 PMC: 11830812. DOI: 10.3389/fphar.2025.1528250.

Evaluation of exo-long noncoding RNA MALAT1 in OSCC in comparison to dysplastic and normal: A cross-sectional study.

Sekar R, Jayaraman S, Veeraraghavan V, Krishnamoorthy K, Aramanai S, Natarajan S J Oral Biol Craniofac Res. 2025; 15(1):123-128.

PMID: 39850457 PMC: 11754077. DOI: 10.1016/j.jobcr.2024.12.018.

VMP1: a multifaceted regulator of cellular homeostasis with implications in disease pathology.

Tong J, Wang Q, Gao Z, Liu Y, Lu C Front Cell Dev Biol. 2024; 12:1436420.

PMID: 39100095 PMC: 11294092. DOI: 10.3389/fcell.2024.1436420.

References

Borges A, de Souza M, da Fonseca A, Wermelinger G, Ribeiro R, Amaral A . Chemoselective Synthesis of Mannich Adducts from 1,4-Naphthoquinones and Profile as Autophagic Inducers in Oral Squamous Cell Carcinoma. Molecules. 2023; 28(1). PMC: 9822194. DOI: 10.3390/molecules28010309. View

Zhang L, Wu J, Ling M, Zhao L, Zhao K . The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015; 14:87. PMC: 4498560. DOI: 10.1186/s12943-015-0361-x. View

Carnero A, Paramio J . The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol. 2014; 4:252. PMC: 4172058. DOI: 10.3389/fonc.2014.00252. View

Hemmings B, Restuccia D . PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012; 4(9):a011189. PMC: 3428770. DOI: 10.1101/cshperspect.a011189. View

Vo T, Wee Y, Cheng H, Wu C, Chen Y, Tuan V . Surfactin induces autophagy, apoptosis, and cell cycle arrest in human oral squamous cell carcinoma. Oral Dis. 2021; 29(2):528-541. DOI: 10.1111/odi.13950. View

Han H, Kim H, Jeong S, Lim D, Ryu M . Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac J Cancer Prev. 2014; 15(16):6939-44. DOI: 10.7314/apjcp.2014.15.16.6939. View

Castel P, Toska E, Engelman J, Scaltriti M . The present and future of PI3K inhibitors for cancer therapy. Nat Cancer. 2022; 2(6):587-597. PMC: 8809509. DOI: 10.1038/s43018-021-00218-4. View

Huang J, Manning B . A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37(Pt 1):217-22. PMC: 2778026. DOI: 10.1042/BST0370217. View

Yen C, Chiang W, Liu S, Cheng P, Lee S, Hong W . Long-term stimulation of areca nut components results in increased chemoresistance through elevated autophagic activity. J Oral Pathol Med. 2013; 43(2):91-6. DOI: 10.1111/jop.12102. View

10.

Polivka Jr J, Janku F . Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013; 142(2):164-75. DOI: 10.1016/j.pharmthera.2013.12.004. View

11.

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B . Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021; 2(3):315-340. PMC: 8554658. DOI: 10.1002/mco2.55. View

12.

Lin C, Wang Y, Huang J, Hung C, Chen J . Autophagy and reactive oxygen species modulate cytotoxicity induced by suppression of ATM kinase activity in head and neck cancer cells. Oral Oncol. 2012; 48(11):1152-8. DOI: 10.1016/j.oraloncology.2012.05.020. View

13.

Roy N, Monisha J, Padmavathi G, Lalhruaitluanga H, Kumar N, Singh A . Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma. Biomolecules. 2019; 9(7). PMC: 6681224. DOI: 10.3390/biom9070253. View

14.

Zhang X, Tang N, Hadden T, Rishi A . Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011; 1813(11):1978-86. DOI: 10.1016/j.bbamcr.2011.03.010. View

15.

Cui B, Lin H, Yu J, Yu J, Hu Z . Autophagy and the Immune Response. Adv Exp Med Biol. 2019; 1206:595-634. PMC: 7120363. DOI: 10.1007/978-981-15-0602-4_27. View

16.

Cham J, Venkateswaran A, Bhangoo M . Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article. Clin Genitourin Cancer. 2021; 19(6):563.e1-563.e7. DOI: 10.1016/j.clgc.2021.07.014. View

17.

Inui T, Chano T, Takikita-Suzuki M, Nishikawa M, Yamamoto G, Okabe H . Association of p62/SQSTM1 excess and oral carcinogenesis. PLoS One. 2013; 8(9):e74398. PMC: 3782476. DOI: 10.1371/journal.pone.0074398. View

18.

Zhu D, Yuan Y, Qiao J, Yu C, Yang X, Wang L . Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma. Cancer Lett. 2014; 356(2 Pt B):773-80. DOI: 10.1016/j.canlet.2014.10.024. View

19.

Mishra R, Patel H, Alanazi S, Kilroy M, Garrett J . PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci. 2021; 22(7). PMC: 8037248. DOI: 10.3390/ijms22073464. View

20.

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View